MedTrace Logo

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

NCT00535730 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 473

Last updated 2017-04-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.

Conditions

  • Herpes Zoster
  • Pneumococcal Infection

Interventions

BIOLOGICAL

Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™

0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period

BIOLOGICAL

Comparator: placebo (concomitant-vaccine matched)

Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.

BIOLOGICAL

Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-02-29
Completion
2008-02-29

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535730 on ClinicalTrials.gov